S. Srinivas

1.2k total citations
38 papers, 816 citations indexed

About

S. Srinivas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, S. Srinivas has authored 38 papers receiving a total of 816 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in S. Srinivas's work include Renal cell carcinoma treatment (15 papers), Cancer Genomics and Diagnostics (9 papers) and Renal and related cancers (8 papers). S. Srinivas is often cited by papers focused on Renal cell carcinoma treatment (15 papers), Cancer Genomics and Diagnostics (9 papers) and Renal and related cancers (8 papers). S. Srinivas collaborates with scholars based in United States, France and Japan. S. Srinivas's co-authors include George A. Fisher, Melinda L. Telli, Ronald Witteles, Ulka N. Vaishampayan, Toni K. Choueiri, R. J. Amato, Ralph J. Hauke, Frede Donskov, Sumanta K. Pal and Fairooz F. Kabbinavar and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

S. Srinivas

37 papers receiving 799 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Srinivas United States	13	527	410	282	264	137	38	816
I. Chen United States	7	422 0.8×	322 0.8×	234 0.8×	203 0.8×	85 0.6×	9	587
Anne Flörcken Germany	17	460 0.9×	357 0.9×	320 1.1×	229 0.9×	26 0.2×	61	889
Thorsten Ruf Switzerland	9	498 0.9×	180 0.4×	388 1.4×	148 0.6×	209 1.5×	20	807
Marilyn Mulay United States	11	250 0.5×	243 0.6×	365 1.3×	104 0.4×	66 0.5×	17	644
Davide Bimbatti Italy	13	398 0.8×	173 0.4×	205 0.7×	158 0.6×	47 0.3×	56	560
Youn Choi Park United States	8	617 1.2×	125 0.3×	548 1.9×	120 0.5×	199 1.5×	13	1.0k
Jean Philippe Spano France	11	363 0.7×	156 0.4×	418 1.5×	220 0.8×	44 0.3×	16	815
Sasja F. Mulder Netherlands	12	340 0.6×	265 0.6×	253 0.9×	130 0.5×	19 0.1×	38	669
Sven Gogov Switzerland	12	409 0.8×	294 0.7×	351 1.2×	145 0.5×	29 0.2×	25	804
Jeffrey C. LaRochelle United States	10	726 1.4×	534 1.3×	140 0.5×	287 1.1×	86 0.6×	13	873

Countries citing papers authored by S. Srinivas

Since Specialization

Citations

This map shows the geographic impact of S. Srinivas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Srinivas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Srinivas more than expected).

Fields of papers citing papers by S. Srinivas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Srinivas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Srinivas. The network helps show where S. Srinivas may publish in the future.

Co-authorship network of co-authors of S. Srinivas

This figure shows the co-authorship network connecting the top 25 collaborators of S. Srinivas. A scholar is included among the top collaborators of S. Srinivas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Srinivas. S. Srinivas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vidyalakshmi, K, et al.. (2025). P-876. Factors Influencing Outcome in Patients Admitted with Melioidosis- A Single Centre Retrospective Study. Open Forum Infectious Diseases. 12(Supplement_1). 1 indexed citations

Srinivas, S., et al.. (2025). The Immunoglobulin A Nephropathy Renaissance: From Pathogenesis to Personalized Therapy. Cureus. 17(11). e97999–e97999.

Martinez, Ernesto Calderón, et al.. (2024). The effects of omega‐3, DHA, EPA, Souvenaid® in Alzheimer's disease: A systematic review and meta‐analysis. Neuropsychopharmacology Reports. 44(3). 545–556. 11 indexed citations

Sridhar, Srikala S., Peter H. O’Donnell, Thomas W. Flaig, et al.. (2023). 2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC). Annals of Oncology. 34. S1203–S1203. 5 indexed citations

Pal, Sumanta K., Cristina Suárez, William Kevin Kelly, et al.. (2020). 702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study. Annals of Oncology. 31. S554–S554. 10 indexed citations

Hoimes, Christopher, Jonathan E. Rosenberg, S. Srinivas, et al.. (2019). EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Annals of Oncology. 30. v356–v356. 44 indexed citations

Stukalin, Igor, J. Connor Wells, Jeffrey Graham, et al.. (2019). Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Current Oncology. 26(2). 175–179. 22 indexed citations

Oliveira, Cleyton Zanardo de, Fabio Kater, Fernando Cotait Maluf, et al.. (2018). Non-metastatic castration-resistant prostate cancer (nmCRPC): Meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide. Annals of Oncology. 29. viii279–viii279. 2 indexed citations

Bamias, Aristotelis, Kimon Tzannis, Michalis Liontos, et al.. (2016). Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database. Annals of Oncology. 27. vi278–vi278. 1 indexed citations

10.

Necchi, Andrea, Guru Sonpavde, Salvatore Lo Vullo, et al.. (2016). Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC). Annals of Oncology. 27. vi277–vi277. 1 indexed citations

11.

Ko, Jenny J., Toni K. Choueiri, Brian I. Rini, et al.. (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. British Journal of Cancer. 110(8). 1917–1922. 58 indexed citations

12.

Heng, D.Y.C., Toni K. Choueiri, Brian I. Rini, et al.. (2013). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of Oncology. 25(1). 149–154. 113 indexed citations

13.

Fishman, Mayer, S. Srinivas, Ralph J. Hauke, et al.. (2013). Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma. European Journal of Cancer. 49(13). 2841–2850. 25 indexed citations

14.

Wilson, Leslie, et al.. (2012). PCN72 Cost Effectiveness Analysis of New Treatments for Metastatic Castration-Resistant Prostate Cancer: Does Severity Matter?. Value in Health. 15(4). A220–A221. 1 indexed citations

15.

Telli, Melinda L., Ronald Witteles, George A. Fisher, & S. Srinivas. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Annals of Oncology. 19(9). 1613–1618. 207 indexed citations

16.

Agarwal, Rajni, Christopher C. Dvorak, Keith Stockerl‐Goldstein, Laura Johnston, & S. Srinivas. (2008). High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. Bone Marrow Transplantation. 43(7). 547–552. 5 indexed citations

17.

Katznelson, Laurence, Kyla Kent, & S. Srinivas. (2007). The effects of intermittent androgen deprivation therapy (ADT) and zoledronic acid administration on bone density in patients with prostate cancer. Journal of Clinical Oncology. 25(18_suppl). 15593–15593. 3 indexed citations

18.

Amato, R. J., Martin L. Dalton, Qihui Zhai, et al.. (2007). A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). Journal of Clinical Oncology. 25(18_suppl). 5026–5026. 67 indexed citations

19.

Bukowski, Ronald M., Fairooz F. Kabbinavar, Robert A. Figlin, et al.. (2006). Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). Journal of Clinical Oncology. 24(18_suppl). 4523–4523. 57 indexed citations

20.

Small, Eric J., et al.. (1996). Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer.. Journal of Clinical Oncology. 14(5). 1617–1625. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact